Mel Ziman

Prof. Mel Ziman

orcid

Research Focus & Metrics

Academic Career Length

49Years (1978-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2016 in Autoimmunity Reviews
Verified
Journal Article
Open access
PZP. Zaenker
P. Zaenker
Elin GrayElin Gray
Elin Gray
MZMel Ziman
Mel Ziman
A link between autoimmune responses and cancer via autoantibodies was first described in the 1950s. Since, autoantibodies have been studied for their potential use as cancer biomarkers, however the exact causes of their production remain to be elucidated. This review summarizes current theories of the causes of autoantibody production in cancer, namely: 1) defects in tolerance and inflammation, 2) changes in protein expression levels, 3) altered protein structure, and 4) cellular death mechanisms. We also highlight the need for further research into this field to improve our understanding of autoantibodies as biomarkers for cancer development and progression.

1 January 2005
Verified
Journal Article
Closed access
KMK Michalczyk
K Michalczyk
MZMel Ziman
Mel Ziman

1 May 1996 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
PMPeter N. Meissner
Peter N. Meissner
TDTamara A. Dailey
Tamara A. Dailey
RHRichard J. Hift
Richard J. Hift
MZMel Ziman
Mel Ziman
ACAnne V. Corrigall
Anne V. Corrigall
HDHarry A. Dailey
Harry A. Dailey

1 July 2009 in Cancer Letters
Verified
Journal Article
Closed access
ECElizabeth Charytonowicz
Elizabeth Charytonowicz
CCCarlos Cordon-Cardo
Carlos Cordon-Cardo
IMIgor Matushansky
Igor Matushansky
MZMel Ziman
Mel Ziman

7 December 2012 in European Journal of Neurology
Verified
Journal Article
Closed access
PDF file
JTJ. A. Thompson
J. A. Thompson
Travis CruickshankTravis Cruickshank
Travis Cruickshank
LPL. E. Penailillo
L. E. Penailillo
JLJ. W. Lee
J. W. Lee
RNR. U. Newton
R. U. Newton
MZMel Ziman
Mel Ziman

15 January 2015 in Brain and Behavior
Verified
Journal Article
Open access
PDF file
Travis CruickshankTravis Cruickshank
Travis Cruickshank
JTJennifer A. Thompson
Jennifer A. Thompson
JDJuan F. Domínguez D
Juan F. Domínguez D
ARAlvaro Reyes
Alvaro Reyes
MBMike Bynevelt
Mike Bynevelt
MZMel Ziman
Mel Ziman
Background: There is a wealth of evidence detailing gray matter degeneration and loss of cognitive function over time in individuals with Huntington's disease (HD). Efforts to attenuate disease‐related brain and cognitive changes have been unsuccessful to date. Multidisciplinary rehabilitation, comprising motor and cognitive intervention, has been shown to positively impact on functional capacity, depression, quality of life and some aspects of cognition in individuals with HD. This exploratory study aimed to evaluate, for the first time, whether multidisciplinary rehabilitation can slow further deterioration of disease‐related brain changes and related cognitive deficits in individuals with manifest HD.Methods: Fifteen participants who manifest HD undertook a multidisciplinary rehabilitation intervention spanning 9 months. The intervention consisted of once‐weekly supervised clinical exercise, thrice‐weekly self‐directed home based exercise and fortnightly occupational therapy. Participants were assessed using MR imaging and validated cognitive measures at baseline and after 9 months.Results: Participants displayed significantly increased gray matter volume in the right caudate and bilaterally in the dorsolateral prefrontal cortex after 9 months of multidisciplinary rehabilitation. Volumetric increases in gray matter were accompanied by significant improvements in verbal learning and memory (Hopkins Verbal Learning‐Test). A significant association was found between gray matter volume increases in the dorsolateral prefrontal cortex and performance on verbal learning and memory.Conclusions: This study provides preliminary evidence that multidisciplinary rehabilitation positively impacts on gray matter changes and cognitive functions relating to verbal learning and memory in individuals with manifest HD. Larger controlled trials are required to confirm these preliminary findings.